Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5 Suppl 7
pubmed:dateCreated
1997-6-9
pubmed:abstractText
Our understanding of the pathogenesis of Alzheimer's disease (AD) had advanced rapidly, particularly in the area of genetics. Clinical trials of agents that offer the promise of going beyond symptomatic treatment to actually slowing the progression of disease, perhaps by enhancing the viability of neurons, are under way. Most of the ideas for therapeutic approaches that may slow progression of disease have come from a combination of epidemiologic and basic science observations. Anti-inflammatory agents, nicotine, estrogens, and free radical scavengers are major areas of inquiry. In addition to being a biological condition of considerable complexity, AD is also challenging from a social and cultural perspective. An appreciation of the changes occurring in our scientific and clinical environments may lead to building more effective bridges between science and society and to better diagnostic and therapeutic approaches to AD.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0028-3878
pubmed:author
pubmed:issnType
Print
pubmed:volume
48
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S2-7
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Genesis of Alzheimer's disease.
pubmed:affiliation
Department of Neurology, Case Western Reserve University, Cleveland, OH, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Review